Senex Biotechnology
Biotechnology, 715 Sumter St, Columbia, South Carolina, 29208, United States, 1-10 Employees
Phone Number: +18*********
Who is SENEX BIOTECHNOLOGY
Senex is a clinical stage company focused on preventing transcriptional reprogramming, a process by which cancer cells modify gene expression to adapt to adversarial conditions; such adap...
Read More
-
Headquarters: 715 Sumter St, Columbia, South Carolina, 29208, United States
-
Date Founded: 2002
-
Employees: 1-10
-
Revenue: Under $1 Million
-
Active Tech Stack: See technologies
Industry: Biotechnology
SIC Code: 8731
|
NAICS Code: 424210 |
Show More
Does something look wrong? Fix it. | View contact records from SENEX BIOTECHNOLOGY
Email
Phone
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Senex Biotechnology
Answer: Senex Biotechnology's headquarters are located at 715 Sumter St, Columbia, South Carolina, 29208, United States
Answer: Senex Biotechnology's phone number is +18*********
Answer: Senex Biotechnology's official website is https://senexbio.com
Answer: Senex Biotechnology's revenue is Under $1 Million
Answer: Senex Biotechnology's SIC: 8731
Answer: Senex Biotechnology's NAICS: 424210
Answer: Senex Biotechnology has 1-10 employees
Answer: Senex Biotechnology is in Biotechnology
Answer: Senex Biotechnology contact info: Phone number: +18********* Website: https://senexbio.com
Answer: Senex is a clinical stage company focused on preventing transcriptional reprogramming, a process by which cancer cells modify gene expression to adapt to adversarial conditions; such adaptation leads to cancer drug resistance and metastasis. Senexs lead program targets CDK8/19 Mediator Kinase, a protein complex that regulates transcription, but not cell cycle progression. Since CDK8/19 is not essential for adult organisms, its inhibition suppresses drug resistance and metastasis without unwanted side effects. Senex is developing highly selective small-molecule inhibitors of this protein for the treatment of presently incurable types of prostate cancer and breast cancer. The Companys lead clinical program, targeting castration resistant prostate cancer (CRPC), is currently supported by a $1.05 million Translational Science Award from the Department of Defense Prostate Cancer Program (DoD PCRP). The preliminary data are robust and comprehensive in their support and validation of their goal to take SNX631-6 to clinical trials for the treatment of CRPC, DoD PCRP reviewer. SNX631-6, the Companys clinical candidate, is an orally available, selective CDK8/19 inhibitor with nanomolar potency, outstanding selectivity, favorable pharmacokinetics and supratherapeutic toleration in repeat dose range finding studies in murine and primate models. The preliminary data convincingly indicate the ability of SNX631-6 to inhibit development in CRPC of drug resistance, inhibit growth of bone-resident tumors, inhibit angiogenesis, and suppress expression of tumor-promoting genes in the cancer cells, DoD PCRP reviewer.
Answer:
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month